Screener
Collegium Pharmaceutical, Inc. COLL Belbuca — 2030
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.
The source filing: Collegium Pharmaceutical, Inc.’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 7:34 AM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-011992
| Years ended December 31, | Jornay PM | Belbuca | Nucynta Products | Symproic | Total |
|---|---|---|---|---|---|
| 2026 | $83,829 | $75,393 | $27,692 | $7,285 | $194,199 |
| 2027 | 83,829 | — | — | 7,285 | 91,114 |
| 2028 | 83,829 | — | — | 7,285 | 91,114 |
| 2029 | 83,829 | — | — | 7,285 | 91,114 |
| 2030 | 83,829 | — | — | 7,285 | 91,114 |
| Thereafter | 104,783 | — | — | 6,072 | 110,855 |
| Remaining amortization expense | $523,928 | $75,393 | $27,692 | $42,497 | $669,510 |
Item 16. Form 10-K Summary
FAQ
- What is Collegium Pharmaceutical, Inc.'s belbuca — 2030?
- Collegium Pharmaceutical, Inc. (COLL) reported belbuca — 2030 of $0 in Q4 2025.
- What does belbuca — 2030 mean?
- Represents the specific financial contribution or performance target attributed to the Belbuca product line for the fiscal year 2030. This metric serves as a milestone for evaluating the product's market durability and the impact of patent exclusivity or competitive entry over a multi-year horizon. It provides a clear benchmark for long-term strategic planning and valuation.
Ask your AI about Collegium Pharmaceutical, Inc.'s belbuca — 2030.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude